Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call

Rhea-AI Summary

Ironwood Pharmaceuticals (NASDAQ: IRWD) announced an investor update conference call for its fourth quarter and full year 2021, scheduled for February 17, 2022, at 8:30 a.m. ET. Participants can dial in at (888) 330-2384 for US/Canada or (240) 789-2701 internationally, using conference ID 4671230. The call will be available for replay after 11:30 a.m. ET on the same day until March 3, 2022. Ironwood is focused on advancing treatments for gastrointestinal diseases, led by its product LINZESS®.

BOSTON--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, February 17, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting Thursday, February 17, 2022 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on March 3, 2022. To listen to the replay, dial (800) 770-2030 (U.S. and Canada) or (647) 362-9199 (international) using conference ID number 4671230. The archived webcast will be available on Ironwood’s website for 14 days beginning approximately one hour after the call has completed.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005009/en/

Investors:

Matt Roache, 617-621-8395

Director, Investor Relations

mroache@ironwoodpharma.com

Source: Ironwood Pharmaceuticals, Inc.

FAQ

When will Ironwood Pharmaceuticals hold its fourth quarter 2021 investor update conference call?

Ironwood Pharmaceuticals will hold its fourth quarter 2021 investor update conference call on February 17, 2022, at 8:30 a.m. Eastern Time.

How can I participate in Ironwood's investor update conference call?

To participate in Ironwood's investor update conference call, dial (888) 330-2384 for US/Canada or (240) 789-2701 internationally, using conference ID 4671230.

What is the replay availability for Ironwood's February 17, 2022 call?

The replay of Ironwood's call will be available starting at 11:30 a.m. ET on February 17, 2022, until 11:59 p.m. ET on March 3, 2022.

What is Ironwood Pharmaceuticals focused on?

Ironwood Pharmaceuticals is focused on advancing treatments for gastrointestinal diseases, including their leading product, LINZESS®.

Where can I find more information about Ironwood Pharmaceuticals?

Further information about Ironwood Pharmaceuticals can be found on their official website at www.ironwoodpharma.com.